The genetic research results accumulating along with the development of technology have been mentioned several times in society, but there are many people who don't know about genome in detail. Nevertheless, Shang Cheol Shin, CEO of EONE-DIAGNOMICS Genome Center(EDGC), predicts that genome would be close to real life in the next few years.

EDGC aims to be a 'personalized service company based on genomic precision medicine' - Prevention of disease by analysing individual's genome, diagnosis of disease by collective diagnosis, target(personalized) treatment reflecting individual genome characteristics, health management based on individual's genomic information analysis.

Also, Mygenomebox is an open platform for genome-based global business, which is constructed to enhance the usefulness by linking genome analysis with real life independently of genetic testing services. This is a 'DNA App Store' that helps consumers easily understand their genetic characteristic regardless of gene knowledge.

However, we have a relatively insufficient environment in which the genome industry can rapidly develop. The US Food and Drug Administration(FDA) recommends to consider genomic data when conducting drug development and national supported research is required to open the results. On the other hand, there are limitations to develop genomic data service industry because of various policy regulations such as the bioethics law in Korea. The lack of attention from medical world to the genome is challenge as well.

Shin said, "Genetic information services are able to become more sophisticated as data is shared more and more. ... If the data sharing in genomic field and the social interests to the industry are getting increased, Korea will be able to lead the global genomic-based services industry."